The novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide decreases nicotine-induced dopamine metabolism in rat nucleus accumbens.

TitleThe novel nicotinic receptor antagonist N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide decreases nicotine-induced dopamine metabolism in rat nucleus accumbens.
Publication TypeJournal Article
Year of Publication2008
JournalEuropean journal of pharmacology
Volume601
Issue1-3
Pagination103-5
Date Published2008
ISSN0014-2999
Abstract

The current study examined the effect of the novel nicotinic acetylcholine receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), on nicotine-induced dopamine metabolism in rat nucleus accumbens, striatum and medial prefrontal cortex. Acute nicotine (0.5 mg/kg, s.c.) produced an increase in the content of dihydroxyphenylacetic acid (DOPAC) in nucleus accumbens, but not in striatum or medial prefrontal cortex. Pretreatment with bPiDDB (1 or 3 mg/kg, s.c.) dose-dependently inhibited the nicotine-induced increase in DOPAC content in nucleus accumbens. These results indicate that bPiDDB inhibits the nicotine-induced increase in DOPAC in reward-relevant brain region targeting nicotinic acetylcholine receptors.

URLhttps://linkinghub.elsevier.com/retrieve/pii/S0014-2999(08)01073-X
DOI10.1016/j.ejphar.2008.10.037
Short TitleEur J Pharmacol
X
Enter your linkblue username.
Enter your linkblue password.
Secure Login

This login is SSL protected

Loading